Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.86 USD | +0.23% | +3.36% | -18.44% |
03:31pm | Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients | MT |
02:38pm | Bristol Myers: positive results in liver cancer | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.44% | 84.67B | |
+42.60% | 748B | |
+34.11% | 598B | |
-5.84% | 356B | |
+18.33% | 325B | |
+4.86% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.85% | 166B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint